We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SYGNIS to Present its Innovative TruePrime™ and SunScript™ Technologies

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "SYGNIS to Present its Innovative TruePrime™ and SunScript™ Technologies"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SYGNIS AG has announced that it will present its proprietary portfolio of TruePrime™ and SunScript™ technologies for DNA amplification and sequencing at the Annual Meeting of the American Society of Human Genetics (ASHG), the ASHG 2015, which will be held from October 6 - 10, 2015 in Baltimore, Maryland.

The ASHG is the largest human genetics meeting worldwide with more than 6,500 attendees and over 200 exhibiting companies and represents a forum for presentations and discussions of cutting-edge science in all areas of human genetics.

Miguel Viribay Vice President Marketing and Sales at SYGNIS and Ángel J. Picher, Associate Director, Product Development will promote both the TruePrime™ and SunScript™ product lines at the Company’s own booth (number 2019). In addition, they will highlight and discuss the latest results of deep sequencing obtained with the TruePrime™ technology, that show superior genome coverage even from single cells when compared to traditional competing technologies, with key opinion leaders and potential future partners from the human genomics field.

“After rolling out our proprietary portfolio of products for DNA amplification and sequencing in Europe and building a strong network of distributors to cover the European markets, we are now moving forward in our product and commercialization strategy to more actively promote our products in the U.S., the main market for our innovative technologies,” commented Pilar de la Huerta, CEO and CFO of SYGNIS AG. “Presenting and hosting an own booth on a conference like the ASHG 2015, the most renowned event in the field of human genetics, is a huge opportunity for us to increase and improve the visibility of our products and technologies in U.S. markets.”